vTv Therapeutics Inc. — fact timeline

vTv Therapeutics Inc. reported first quarter ended March 31, 2026 results: revenue $36,839, net income Net income attributable to vTv shareholders for the three months ended March 31, 2026, was $24.1 million, EPS $1.94 and $1.65 per basic and diluted share, respectively.

“$ 89,899 vTv Therapeutics Inc. Condensed Consolidated Statements of Operations (in thousands, except per share data) Three Months Ended March 31, 2026 2025 (Unaudited) Revenue $ 36,839 $ — Operating expenses: Research and development 8,978 2,830 General and administrative 4,598 3,673 Total operating expenses 13,576 6,503 Operating income/(loss) 23,263 (6,503)”

vTv Therapeutics Inc. reported financial results for the full year ended December 31, 2025.

“vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes ("T1D"), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on recent corporate developments.”

vTv Therapeutics Inc. reported the fourth quarter ended December 31, 2025 results: net income $7.1 million, EPS $0.58 per basic share.

“Net loss attributable to vTv shareholders for the three months ended December 31, 2025, was $7.1 million or $0.58 per basic share.”

vTv Therapeutics Inc. entered into Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. valued at $20 million upfront fee, up to $50 million in development milestones, $65 million in sales-related m (effective 2026-01-30).

“On January 30, 2026, vTv Therapeutics LLC (“vTv LLC” or the "Company"), a subsidiary of vTv Therapeutics Inc., entered into the Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. (“Newsoara”) (the “Second Amendment”) to amend the License Agreement previously entered into between vTv LLC and Newsoara on May 31, 2018 (the “Original Agreement”).”

vTv Therapeutics Inc.: Reduced quorum requirement for stockholder meetings to 33.4% (effective 2025-12-19).

“On December 19, 2025, the Board of Directors of vTv Therapeutics Inc. (the Company) amended Section 2.8 of Article II of the Company’s Second Amended and Restated By-Laws to reduce the quorum requirement for any meeting of stockholders to 33.4%.”

Michael Tung was appointed as executive vice president and chief financial officer at vTv Therapeutics Inc..

“On May 19, 2025, vTv Therapeutics Inc. (the “Company”) announced that the Company has appointed Michael Tung as executive vice president and chief financial officer of the Company, effective as of May 19, 2025.”

Barry K. Brown was appointed as interim principal financial officer at vTv Therapeutics Inc..

“On April 11, 2025, the Board of Directors of vTv Therapeutics Inc. (the “Company”) appointed Barry K. Brown, age 64, as interim principal financial officer effective immediately.”

Steven Tuch resigned as Executive Vice President and Chief Financial Officer at vTv Therapeutics Inc..

“On February 24, 2025, Steven Tuch, Executive Vice President and Chief Financial Officer of vTv Therapeutics Inc. (the "Company"), informed the Company of his intention to resign from his position effective March 21, 2025.”

vTv Therapeutics Inc. reported financial results for the first quarter ended March 31, 2024.

“On May 9, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended March 31, 2024.”

Howard Weiner resigned as director at vTv Therapeutics Inc..

“John Fry and Howard Weiner resigned from their director roles effective upon the filing of the 2023 Annual Report.”

John Fry resigned as director at vTv Therapeutics Inc..

“John Fry and Howard Weiner resigned from their director roles effective upon the filing of the 2023 Annual Report.”

Anne Phillips was elected as director at vTv Therapeutics Inc..

“On March 12, 2024, Anne Phillips was elected as director of vTv Therapeutics, Inc. (the “Company”), effective and contingent on the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, which occurred on March 13, 2024 (the “2023 Annual Report”).”

vTv Therapeutics Inc. reported financial results for the fiscal year ended December 31, 2023.

“On March 13, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2023.”

vTv Therapeutics Inc. amended G42 Amendment with G42 Investments AI Holdings RSC Ltd (effective 2024-02-27).

“the Company entered into an amendment to the Common Stock Purchase Agreement with G42 Investments AI Holdings RSC Ltd (“G42”) (the “G42 Amendment”), on February 27, 2024”

vTv Therapeutics Inc. entered into Registration Rights Agreement with the Purchasers (effective 2024-02-27).

“On February 27, 2024, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchasers, pursuant to which the Company agreed to register for resale the Shares and the Warrant Shares held by the Purchasers”

vTv Therapeutics Inc. entered into Securities Purchase Agreement with certain institutional accredited investors valued at aggregate gross proceeds of approximately $51.0 million (effective 2024-02-27).

“On February 27, 2024, vTv Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) (i) an aggregate of 464,377 shares (the “Shares”) of the Company’s Class A common stock, par value $0.01 per share (the “Common Stock”), at a purchase price of $11.81 per share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 3,853,997 shares of Common Stock (the “Warrant Shares”) at a purchase price of $11.80 per Pre-Funded Warrant”

vTv Therapeutics Inc. reported preliminary financial results for fiscal year ended December 31, 2023.

“Preliminary Financial Results - Cash Balance as of December 31, 2023 Based upon preliminary estimates and information available to the Company, it expects to report that it had cash and cash equivalents of approximately $9.4 million as of December 31, 2023.”

Srinivas Akkaraju was elected as Director at vTv Therapeutics Inc..

“Raymond Cheong and Srinivas Akkaraju were each elected as directors of the Company, effective and contingent on the closing of the Private Placement.”

Raymond Cheong was elected as Director at vTv Therapeutics Inc..

“Raymond Cheong and Srinivas Akkaraju were each elected as directors of the Company, effective and contingent on the closing of the Private Placement.”

Keith Harris resigned as Director at vTv Therapeutics Inc..

“Keith Harris agreed to resign as a member of the Board and the Audit Committee of the Board, effective following the later of (a) the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and (b) the appointment of a director pursuant to Section 7.9(c) of the Securities Purchase Agreement.”

Howard L. Weiner resigned as Director at vTv Therapeutics Inc..

“Howard L. Weiner agreed to resign as a member of the Board and the Audit Committee of the Board, effective as of the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.”

John A. Fry resigned as Director at vTv Therapeutics Inc..

“John A. Fry agreed to resign as a member of the Board, the Audit Committee and Nominating and Corporate Governance Committee of the Board and Howard L. Weiner agreed to resign as a member of the Board and the Audit Committee of the Board, effective as of the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.”

Hersh Kozlov resigned as Director at vTv Therapeutics Inc..

“Hersh Kozlov resigned as a member of the Board, the Compensation Committee and Nominating and Corporate Governance Committee of the Board, effective and contingent on the closing of the Private Placement.”

Jonathan Isaacsohn resigned as Director at vTv Therapeutics Inc..

“Jonathan Isaacsohn resigned as a member of the Board”

vTv Therapeutics Inc. entered into Sales Agreement with Cowen and Company, LLC valued at up to $50.0 million (effective 2024-02-28).

“On February 28, 2024, vTv Therapeutics Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“TD Cowen”), pursuant to which the Company may offer and sell, from time to time, through TD Cowen, as sales agent, shares of the Company’s Class A common stock, par value $0.01 per share, having an aggregate offering price of up to $50.0 million (the “ATM Offering”).”

vTv Therapeutics Inc. terminated License Agreement between vTv Therapeutics LLC and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. valued at Notice of intent to terminate received on December 18, 2023; termination effective after negotiation (effective 2023-12-18).

“On December 18, 2023, vTv Therapeutics LLC (“vTv LLC”), a controlled subsidiary of vTv Therapeutics Inc. (the “Company”), received notice from Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”) of their intent to terminate the License Agreement between vTv LLC and Huadong, dated as of December 21, 2017, as amended January 14, 2021 (the “Agreement”).”

Chandresh Harjivan resigned as member of the board of directors at vTv Therapeutics Inc..

“On December 18, 2023, Chandresh Harjivan resigned as a member of the board of directors (the “Board”) of the Company to pursue other opportunities.”

vTv Therapeutics Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“December 13, 2023, vTv Therapeutics Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the requirement of Nasdaq Listing Rule 5550(b)(2) because the Company's listed securities have been below the required market value of listed securities (MVLS) of $35 million for the last 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days, or until June 10, 2024, to regain compliance with Nasdaq Listing Rule 5550(b)(2). Compliance can be achieved without f”

vTv Therapeutics Inc. reported third quarter ended September 30, 2023 results: revenue $ —, net income $6.7 million, EPS $0.08 per basic share.

“Net loss attributable to vTv shareholders for the three months ended September 30, 2023, was $6.7 million or $0.08 per basic share.”

vTv Therapeutics Inc. entered into Common Stock Repurchase Agreement with Reneo Pharmaceuticals, Inc. valued at approximately $4.4 million (effective 2023-10-30).

“On October 30, 2023, vTv Therapeutics LLC (“vTv LLC”), the principal operating subsidiary of vTv Therapeutics, Inc. (the “Company”) entered into a Common Stock Repurchase Agreement (the "Repurchase Agreement") with Reneo Pharmaceuticals, Inc. (“Reneo”) pursuant to which Reneo agreed to purchase all shares of common stock of Reneo that had been owned by vTv LLC. Pursuant to the Repurchase Agreement, Reneo agreed to pay vTv LLC gross proceeds of approximately $4.4 million for the Reneo common stock.”

vTv Therapeutics Inc. reported financial results for second quarter ended June 30, 2023.

“On August 11, 2023, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended June 30, 2023.”

vTv Therapeutics Inc. received a nasdaq extension granted notice regarding minimum bid price.

“July 17, 2023, the Company received notice from Nasdaq that, based upon the completed questionnaire and the expedited review process, it had approved the Company’s request to extend the period for the Company to regain compliance with the Minimum Bid Requirement until December 18, 2023. Nasdaq noted that the extension was based upon the Company’s representation that it would complete a reverse stock split no later than November 22, 2023, at a ratio between 1:10 and 1:20, and that it would obtain stockholder approval for such a reverse stock split on or before October 30, 2023. There can be no”

vTv Therapeutics Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“June 21, 2023, vTv Therapeutics, Inc. (the “Company”) received a notice (the “Delisting Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that Nasdaq has determined the Company did not regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) by June 20, 2023, the deadline to regain compliance with the Rule pursuant to the notice the Company received from Nasdaq on December 22, 2022 (the “Extension Notice”), and therefore the”

vTv Therapeutics Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-06 meeting.

“The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified based on the following results of the voting: For Against Abstain Broker Non Votes 75,554,888 895,657 37,434 0”

vTv Therapeutics Inc. shareholders approved Set frequency of future nonbinding advisory votes on executive compensation at every three years at the 2023-06-06 meeting.

“The Company’s stockholders set the frequency of future nonbinding advisory votes on the compensation paid to the Company’s named executive officers as every three years based upon the following results of the voting: 1 Year 2 Years 3 Years Abstain Broker Non Votes 2,342,432 114,442 63,036,155 307,105. 10,687,845”

vTv Therapeutics Inc. shareholders approved Advisory vote on executive compensation at the 2023-06-06 meeting.

“The Company’s stockholders approved on a nonbinding advisory basis the compensation paid to the Company’s named executive officers based upon the following results of the voting: For Against Abstain Broker Non Votes 64,740,672 911,509 147,953 10,687,845”

vTv Therapeutics Inc. shareholders approved Election of Directors at the 2023-06-06 meeting.

“Based on the following results of the voting, the Company’s stockholders elected the nominees listed below to the Company’s Board of Directors, each to serve for a term to expire at the Company’s 2024 annual meeting of stockholders or until their successors are duly elected and qualified: Director Nominee For Withheld Broker Non Votes John A. Fry 65,554,590 245,544 10,687,845 Chandresh Harjivan 65,530,597 269,537 10,687,845 Keith Harris 65,281,995 518,139 10,687,845 Jonathan Isaacsohn 65,386,409 413,725 10,687,845 Hersh Kozlov 64,477,507 1,322,627 10,687,845 Fahed Al Marzooqi 65,413,332 386,802 10,687,845 Richard S. Nelson 65,280,700 519,434 10,687,845 Paul Sekhri 65,539,487 260,647 10,687,845 Howard L. Weiner 65,392,364 407,770 10,687,845”

vTv Therapeutics Inc. reported the first quarter ended March 31, 2023 results: net income $4.5 million, EPS $0.06 per basic share.

“Net loss attributable to vTv shareholders for the three months ended March 31, 2023, was $4.5 million or $0.06 per basic share.”

vTv Therapeutics Inc. reported the fourth quarter and year ended December 31, 2022 results: net income Net loss attributable to vTv shareholders for the three months ended December 31, 2022, was $4.7 million or $0.06 per ba, EPS $0.06 per basic share.

“vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2022.”

vTv Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 22, 2022, vTv Therapeutics Inc. (the “Company”) received a letter from The NASDAQ Stock Market LLC (“NASDAQ”) notifying the Company that it is not in compliance with the requirement of NASDAQ Rule 5550(a)(2) as a result of the closing bid price of the Company’s Class A common stock (“Class A Common Stock”) being below $1.00 per share for 30 consecutive business days. This notification has no effect on the listing of the Class A Common Stock on The NASDAQ Capital Market at this time. In accordance with NASDAQ Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until June”

Steven Tuch was appointed as Chief Financial Officer at vTv Therapeutics Inc..

“the board of directors of the Company (the “Board”) has appointed Steven Tuch as Chief Financial Officer of the Company, effective as of December 8, 2022.”

vTv Therapeutics Inc. reported the third quarter ended September 30, 2022 results: net income $4.3 million or $0.05 per basic share, EPS $0.05 per basic share.

“Net loss attributable to vTv shareholders for the three months ended September 30, 2022, was $4.3 million or $0.05 per basic share.”

Dr. Jonathan Isaacsohn was appointed as Chair of the Board at vTv Therapeutics Inc..

“appointed Dr. Jonathan Isaacsohn as a member and chair of the Board, effective immediately.”

Richard S. Nelson changed role as Executive Vice President at vTv Therapeutics Inc..

“As of the Effective Date, Richard S. Nelson will cease to be the Interim Chief Executive Officer but will continue to serve as a member of the Board and as an Executive Vice President of the Company.”

Paul Sekhri was appointed as President and Chief Executive Officer at vTv Therapeutics Inc..

“On July 27, 2022, vTv Therapeutics Inc. (the “Company”) announced that the board of directors of the Company (the “Board”) has appointed Paul Sekhri as President and Chief Executive Officer and as a member of the Board, effective as of August 1, 2022”

Dr. Keith Harris was appointed as member of the Board and a member and chair of the Audit Committee of the Board at vTv Therapeutics Inc..

“appointed (i) Dr. Keith Harris as a member of the Board and a member and chair of the Audit Committee of the Board, effective immediately”

Robin E. Abrams resigned as executive chairperson at vTv Therapeutics Inc..

“On April 15, 2022, Robin E. Abrams resigned as executive chairperson of the board of directors (the “Board”) of vTv Therapeutics Inc. (the “Company”) to pursue other opportunities.”

Noel Spiegel departed as Director and Chair of the Audit Committee at vTv Therapeutics Inc..

“On March 30, 2022, Mr. Noel Spiegel, who has served as a director and Chair of the Audit Committee of the Board of vTv Therapeutics Inc. (the “Company”) since its initial public offering in 2015, notified the Company of his decision not to stand for re-election at the Company’s 2022 annual meeting of stockholders.”

Richard S. Nelson was appointed as Chief Executive Officer at vTv Therapeutics Inc..

“On March 1, 2022, the Board appointed Mr. Richard S. Nelson as Acting Chief Executive Officer until the Effective Date, at which time Mr. Nelson will become Interim Chief Executive Officer”

Deepa Prasad resigned as Chief Executive Officer at vTv Therapeutics Inc..

“On February 27, 2022, Ms. Deepa Prasad notified the Board of Directors (the “Board”) of vTv Therapeutics Inc. (the “Company”) of her decision to resign from her positions as Chief Executive Officer, President and Board member, effective as of March 29, 2022”